Yingying Xu
About Yingying Xu
Yingying Xu is the Director of Clinical Operations at BeiGene in Shanghai, China, with over a decade of experience in clinical operations, particularly in oncology.
Director Clinical Operations at BeiGene
Yingying Xu currently holds the role of Director Clinical Operations at BeiGene in Shanghai City, China. In this capacity, she oversees the clinical operations for solid tumor compounds. Xu has been with BeiGene since June 2017, leveraging her extensive experience in clinical operations management and oncology.
Previous Roles at Covance
Prior to her current role, Yingying Xu was with Covance, where she progressed through a series of increasingly senior positions. She began as a Clinical Research Associate (CRA) from 2007 to 2010, then moved to Senior CRA from 2010 to 2011. Xu was promoted to Associate Manager, Clinical Operations from 2011 to 2012, then Manager from 2012 to 2014, Senior Manager from 2014 to 2016, and finally Associate Director from 2016 to 2017. She spent a cumulative total of nearly a decade at Covance, gaining substantial expertise in clinical operations.
Experience at Quintiles
Before Covance, Yingying Xu worked at Quintiles as a Clinical Trial Supply Associate. She held this position from 2005 to 2007, where she managed clinical trial supplies. This early career role laid the foundation for her subsequent focus on clinical operations and management.
Educational Background at Fudan University
Yingying Xu holds a Master’s degree in Medicine from Fudan University, where she studied from 2003 to 2006. Her advanced education has provided her with a strong foundation in medical sciences, which has been instrumental in her career in clinical operations and oncology.
Expertise in Clinical Operations and Oncology
Yingying Xu has over a decade of experience in clinical operations, with a specialized focus on oncology. Her career has been marked by roles that progressively increased in responsibility, particularly in the management of clinical research associates (CRAs) and clinical operations teams. Her leadership in clinical operations for solid tumor compounds at BeiGene is a testament to her expertise in this field.